Nature Communications

Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial

2026-01-28

Full text

DOI https://doi.org/10.1038/s41467-026-68736-2